Feb 14, 2024

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients   Complete Their 30-Day Follow-up; Top-line Results Expected in Second
Feb 12, 2024

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients   Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Q3 2024 and
Jan 31, 2024

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational
Jan 04, 2024

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Financing Led by Leading U.S. Life Sciences-focused Investors PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >